Target intelligence / Profile preview

Very-low-density lipoprotein particle (VLDL)

Target
VLDL
Molecular classification
Lipoprotein, Macromolecular complex, Other
01

Overview

Very-low-density lipoprotein particle (VLDL) is a type of macromolecular complex synthesized by the liver that transports endogenous triglycerides, cholesterol esters, phospholipids, and free cholesterol through the bloodstream to peripheral tissues. Composed mainly (~90%) of various types of fats and ~10% proteins—including apolipoproteins such as apoB100—VLDLs play an essential role in energy distribution and storage within the body. After delivering their cargoes via enzymatic processing by endothelial-bound enzymes like LPL, they are converted into intermediate-density then low-density particles. Elevated circulating levels contribute significantly to cardiovascular disease risk due to their role in promoting arterial plaque formation through deposition within vessel walls[1][2][3].

Other names
Very low-density lipoproteinVLDLTriglyceride-rich lipoprotein (context-dependent)
02

Mechanism of action

Mechanisms relate to modulation of biosynthesis, secretion, or catabolism rather than direct binding. Examples include: - Inhibition of hepatic triglyceride synthesis/secretion - Enhancement of peripheral triglyceride hydrolysis by activating lipoprotein lipase - Reduction in apolipoprotein B100 production

03

Biological functions

Transport of endogenous triglycerides and cholesterol from the liver to peripheral tissuesEnergy storage and regulationPrecursor for intermediate-density (IDL) and low-density (LDL) lipoproteins
04

Disease associations

Cardiovascular disease (notably atherosclerosis)Metabolic syndrome/diabetes-related dyslipidemiaObesity-associated dyslipidemia
05

Safety considerations

Therapeutic challenges include off-target effects from drugs that lower VLDLs—such as hepatotoxicity with statins/fibrates—or paradoxical increases in other lipid fractions.Lowering triglycerides excessively may have unknown long-term effects.
06

Interacting drugs

Statins

2 more in the full profile.

07

Biomarkers

Elevated plasma concentration/levels measured as part of standard lipid panels; high levels are used as biomarkers for cardiovascular risk assessmentApolipoprotein B100

Beyond the preview

Go deeper on Very-low-density lipoprotein particle (VLDL).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Very-low-density lipoprotein particle (VLDL).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call